Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Phone support at (619) 648-1247 is staffed 24/7 and is the only channel open to non-patients
Ovejera et al., 1979
Formal trials of GLP-1 in ADHD-comorbid obesity are underway
Mark Pimental, and Dr
Looking to the future of what this means for GLP-1 deal making, the central message is that obesity is still very much a hot bed as there is need to invest in emerging modalities that can be combined/co-administered with GLP-1s and mitigate risks/target the residual unmet need associated with GLP-1s including the serious side effects such as nausea, vomiting, weight regain and excessive muscle loss
Discov Med 2 , 302 (2025)
